Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cancer screening].

Hideyuki Akaza1, Takashi Tsuruo, Nagahiro Saijo

  • 1Dept. of Urology, University of Tsukuba, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study.

BJUI compass·2022
Same author

[Current Clinical Practice Pattern for Castration-Resistant Prostate Cancer(CRPC)in Japan].

Gan to kagaku ryoho. Cancer & chemotherapy·2021
Same author

A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study.

Japanese journal of clinical oncology·2021
Same author

Prostate cancer in multi-ethnic Asian men: Real-world experience in the Malaysia Prostate Cancer (M-CaP) Study.

Cancer medicine·2021
Same author

Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naïve Prostate Cancer in Japan-Recent Trends and Efficacy.

Gan to kagaku ryoho. Cancer & chemotherapy·2021
Same author

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan.

Japanese journal of clinical oncology·2021
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Cancer screening in Japan aims to reduce cancer morbidity and mortality. Despite government support since 1983, low public uptake remains a challenge, necessitating further improvements in public health initiatives.

Area of Science:

  • Public Health
  • Oncology
  • Health Services Research

Context:

  • Cancer screening programs in Japan have evolved since 1983, with government support shifting to local authorities in 1998.
  • Despite established programs, screening uptake in Japan is low (estimated at 30%), contrasting with higher rates in countries like the USA.

Purpose:

  • To evaluate the effectiveness of cancer screening methods and identify barriers to public uptake.
  • To inform strategies for improving cancer prevention and screening services in Japan.

Summary:

  • Government-supported cancer screening in Japan covers multiple cancer types, including gastric, cervical, lung, breast, endometrial, and colorectal cancers.
  • An evaluation in 2000 confirmed mortality reduction evidence for several screening methods, including cervical cytology, mammography, and fecal occult blood tests.

Related Experiment Videos

  • Barriers to increased screening uptake are multifaceted, encompassing legal, ethical, financial, infrastructural, data, and public education factors.

    • Impact:

    • Establishment of a Research Centre for Cancer Prevention and Screening in 2003 signifies a commitment to enhancing cancer screening services.
    • Ongoing initiatives aim to build upon past progress, though significant challenges remain in improving screening accessibility and public engagement.